Biogen licenses Denali’s amyloid beta programme for Alzheimer’s
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Under the terms, Biogen will handle all the development and commercial activities of ATV: Aβ, along with the related expenses.
Let's personalize your content